EVOLUS, INC.

EOLS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $297.2M $266.3M $202.1M $148.6M $99.7M $56.5M $34.9M
Cost of Revenue $100.1M $84.0M $64.5M $58.8M $43.5M $18.3M $8.0M
Gross Profit $197.1M $182.3M $137.6M $89.8M $56.1M $38.2M $26.9M
Gross Margin 66.3% 68.5% 68.1% 60.4% 56.3% 67.6% 77.1%
Operating Expenses
Research & Development $2.1M $1.7M $4.0M
SG&A Expense $220.8M $198.0M $164.9M $141.8M $112.1M $98.2M $113.6M
Operating Income $-32.7M $-34.4M $-49.2M $-65.3M $-44.4M $-153.1M $-98.9M
Operating Margin -11.0% -12.9% -24.4% -44.0% -44.6% -270.7% -283.3%
Interest Expense $13.8M $9.1M $1.4M
Pretax Income $-51.0M $-49.8M $-61.5M $-74.3M $-46.8M $-162.9M $-105.1M
Income Tax Expense $677.0K $664.0K $176.0K $95.0K $42.0K $77.0K $-15.0M
Net Income $-51.6M $-50.4M $-61.7M $-74.4M $-46.8M $-163.0M $-90.0M
Net Margin -17.4% -18.9% -30.5% -50.1% -47.0% -288.3% -257.8%
EPS (Basic) $-0.80 $-0.81 $-1.08 $-1.33 $-0.94 $-4.83 $-3.19
EPS (Diluted) $-0.80 $-0.81 $-1.08 $-1.33 $-0.94 $-4.83 $-3.19
Shares Outstanding (Basic) 65.1M 64.5M 62.0M 56.9M 56.1M 49.8M 33.7M 33.6M
Shares Outstanding (Diluted) 65.1M 64.5M 62.0M 56.9M 56.1M 49.8M 33.7M 33.6M
Dividends Per Share
← Newer Page 1 of 2 Older →